SARS-CoV-2 Reagents and Services Related Citations

The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in unprecedented crisis to the global health. The SARS-CoV-2 has spread into over 100 countries and sickened over 4.4M people worldwide. A timely response to virus outbreaks in terms of the developments of both diagnostic tools and therapeutics is essential to combat such invisible enemies. To support these studies, Sino Biological has developed a comprehensive panel of antibodies and antigens for SARS-CoV-2. Sino Biological also specializes in recombinant antigen and antibody production. The ProVirTM collection is the world largest viral antigen bank, including over 800 proteins from 350 viral strains.

Up to 15th, May, there are 69 publications that have cited SARS-CoV-2 reagents or services providing by Sino Biological Inc.

1. Wang, C, et al.A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications.2020

2. Ou, X, et al., Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications.2020

3. Renhong Yan,et al.Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science.2020

4. Linlin Bao, et al.The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice.Nature.2020

5. Lamers, MM, et al.SARS-CoV-2 productively infects human gut enterocytes. Science.2020

6. Rockx, B,et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science.2020

7. Long, QX,et al.,Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine.2020

8. Ni, L , et al.Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity.2020

9. Huibin Lv, et al.Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Reports.2020

10. Yunlong Cao, et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.Cell.2020

11. Dora Pinto, et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature.2020

12. Gan, JH,et al,Discovery of small molecule therapeutics for the Middle Eastern respiratory syndrome-coronavirus (MERS-CoV).Thesis.2020

13. Xiao, F et al.Evidence for gastrointestinal infection of SARS-CoV-2.Gastroenterology.2020

14. Sangeun Jeon,et al.Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.Antimicrob Agents Chemother.2020

15. Bing Zhao,et al.Recapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids.Protein&Cell.2020

16. Shan-Meng Lin,et al.Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.J. Med. Chem.2020

17. Liu, X,et al.Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction.Acta Pharm Sin B.2020

18. Yu, P,et al.Age-related rhesus macaque models of COVID-19.Anim Models Exp Med.2020

19. Larsen, CP,et al.Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19).Kidney Int Rep.2020

20. Song, Y;Song,et al.Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.ChemRxiv.2020

21. Pu, T,et al.Evaluate Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity by Pseudoviral Particles.J. Med. Virol.2020

22. Ye, L,et al.Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.Cellular & Molecular Immunology.2020

23. Prasad, ASV,et al.Local Immunity Concept in the Context of the Novel Corona Viral Infection: A Consideration.Asian Journal of Immunology.2020

24. Okba, NMA,et al.Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.Emerging Infect. Dis.2020

25. Seo, G,et al.Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.ACS Nano.2020

26. Su, H,et al.Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.Kidney Int.2020

27. Liu, X,et al.Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.Acta Pharm Sin B.2020

28. Zeng, W,et al.Biochemical characterization of SARS-CoV-2 nucleocapsid protein.Biochemical and Biophysical Research Communications.2020

29. Musarrat, F,et al.The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.J Med Virol.2020

30. Zeng, X,et al.Molecular Detection of SARS-CoV-2 in Formalin Fixed Paraffin Embedded Specimens.JCI Insight.2020

31. Sun, B,et al.Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.Emerg Microbes Infect.2020

32. Zeng, X,et al.Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.Antib Ther.2020

33. Khan, S,et al.Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.BioRxiv.2020

34. Ling Ni,et al.Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2.medRxiv.2020

35. Jiang, H,et al.Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray.medRxiv.2020

36. Bo Diao,et al.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv.2020

37. Thornburg,et al.Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.bioRxiv.2020

38. Bin Ju,et al.Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.medRxiv.2020

39. Linlin Bao,et al.Reinfection could not occur in SARS-CoV-2 infected rhesus macaques.medRxiv.2020

40. Linlin Bao,et al.Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route.medRxiv.2020

41. Chunyun Sun,et al.SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development.bioRxiv.2020

42. Ke Wang,et al.SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.medRxiv.2020

43. Okba, NMA,et al.SARS-CoV-2 specific antibody responses in COVID-19 patients.medRxiv.2020

44. Renhong Yan,et al.Structural basis for the recognition of the 2019-nCoV by human ACE2.medRxiv.2020

45. Milewska, A,et al.HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV.bioRxiv.2020

46. Wang, C,et al.Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2.bioRxiv.2020

47. Li, Y,et al.Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1.bioRxiv.2020

48. Xiong, H,et al.Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells.bioRxiv.2020

49. Zhang, Q,et al.SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation.bioRxiv.2020

50. Zhang, Y,et al.Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry.bioRxiv.2020

51. Feng, Z,et al.The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes.medRxiv.2020

52. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020

53. Tan, X,et al.Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples.bioRxiv.2020

54. Zhu, Y,et al.Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.bioRxiv.2020

55. Zeng, X,et al.Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy.bioRxiv.2020

56. Wei, C,et al.Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies.medRxiv.2020

57. Walter, JD,et al.Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain.BioRxiv.2020

58. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray.BioRxiv.2020

59. Chi, X,et al.Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain.bioRxiv.2020

60. Kim, SY,et al.Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry.bioRxiv.2020

61. Si, L,et al.Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics.bioRxiv.2020

62. Deng, W,et al.Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques.bioRxiv.2020

63. Liu, L,et al.SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner.bioRxiv.2020

64. Zha, L,et al.Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles.bioRxiv.2020

65. McAndrews, KM,et al.Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19.medRxiv.2020

66. Romano, M,et al.An engineered stable mini-protein to plug SARS-Cov2 Spikes.bioRxiv.2020

67. Norman, M,et al.Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients.medRxiv.2020

68. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020

69. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray.BioRxiv.2020

  • 1
  • 2
  • 3
  • 4
  • 5

Here we list part products cited in those publications.